Literature DB >> 32089448

Rapid reconstitution of regulatory T-cell subsets is associated with reduced rates of acute graft-versus-host disease and absence of viremia after cord blood transplantation in children with reduced-intensity conditioning using alemtuzumab.

Xiaohua Chen1, Memphis Hill1, Mark Vander Lugt1, Maria Escolar2, Zhou Fang3, Wei Chen3, Paul Szabolcs4.   

Abstract

Forkhead box P3 (FOXP3)+ regulatory T cell (Treg) reconstitution after unrelated donor umbilical cord blood transplantation in chemotherapy-naïve children is incompletely characterized. We studied 21 children with nonmalignant diseases receiving an identical alemtuzumab-containing regimen. We hypothesized that Treg recovery may be perturbed in patients not only by acute graft-versus-host disease (aGVHD) but also by viremia. Tregs and their memory and naïve subsets were serially monitored for proliferation and apoptosis along with conventional T cells (Tcon). A "reconstitution index" (RI) was calculated relative to pretransplantation values for each parameter. At 3 months post-UCBT, the RI of Tregs was faster compared with other immune components tested and was most rapid in patients free of aGVHD and viremia. There were significantly fewer Tregs in patients experiencing grade I-II aGVHD and/or viremia, leading to an imbalance between Tregs-Tcon ratios. Central and effector memory Tregs were most affected at this time point when they dominated in the circulation. Impaired Treg proliferation without increased apoptosis accounted for the reduced Treg-Tcon ratio. In patients affected with grade II aGVHD and viremia, the overall reduction in circulating Treg pool were associated with a more oligoclonal T-cell receptor β repertoire. Taken together, aGVHD and viremia can lead to defective Treg expansion homeostasis.
Copyright © 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Forkhead box P3; acute graft-versus-host disease; alemtuzumab; regulatory T cell; umbilical cord blood transplantation

Mesh:

Substances:

Year:  2020        PMID: 32089448      PMCID: PMC7263741          DOI: 10.1016/j.jcyt.2020.01.005

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   6.196


  20 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

2.  Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT.

Authors:  A Xhaard; H Moins-Teisserenc; M Busson; M Robin; P Ribaud; N Dhedin; S Abbes; M Carmagnat; V-D Kheav; G Maki; R Peffault de Latour; A Toubert; G Socié
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

3.  Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

Authors:  Ken-ichi Matsuoka; Haesook T Kim; Sean McDonough; Gregory Bascug; Ben Warshauer; John Koreth; Corey Cutler; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

Review 4.  tTregs, pTregs, and iTregs: similarities and differences.

Authors:  Ethan M Shevach; Angela M Thornton
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

Review 5.  Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT).

Authors:  Suhag Parikh; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

6.  A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.

Authors:  Suhag H Parikh; Adam Mendizabal; Cara L Benjamin; Krishna V Komanduri; Jeyaraj Antony; Aleksandra Petrovic; Gregory Hale; Timothy A Driscoll; Paul L Martin; Kristin M Page; Ketti Flickinger; Jerelyn Moffet; Donna Niedzwiecki; Joanne Kurtzberg; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

7.  Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients.

Authors:  Xiaohua Chen; Raymond Barfield; Ely Benaim; Wing Leung; James Knowles; Dawn Lawrence; Mario Otto; Sheila A Shurtleff; Geoffrey A M Neale; Frederick G Behm; Victoria Turner; Rupert Handgretinger
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

8.  Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease.

Authors:  L L Reubsaet; A P J de Pagter; D van Baarle; L Keukens; N Nanlohy; E A M Sanders; B J Prakken; J J Boelens; I M de Kleer
Journal:  Bone Marrow Transplant       Date:  2012-09-24       Impact factor: 5.483

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

Review 10.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

View more
  1 in total

1.  CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT.

Authors:  Ze-Ying Fan; Ting-Ting Han; Wei Zuo; Xiao-Su Zhao; Ying-Jun Chang; Meng Lv; Xiao-Dong Mo; Yu-Qian Sun; Yuan-Yuan Zhang; Yu Wang; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang; Xiang-Yu Zhao
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.